BioPharmSignal logoBioPharmSignal

Biotech News

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

Coherus BioSciences, Inc. (CHRS)Coherus BioSciences, Inc.Earnings

REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00 p.m. Eastern Daylight Time on November 9, 2026, Coherus’ management team will

Related news

KURAKura Oncology2026-11-03 11:58 EST

Kura Oncology to Report Third Quarter Financial Results on November 10

ADMAADMA Biologics2026-10-28 11:00 EST

ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

SNDXSyndax Pharmaceuticals2026-10-26 11:00 EST

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

ANIPANI Pharmaceuticals2026-10-23 10:55 EST

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

GERNGeron2026-10-21 12:00 EST

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

ARGXArgenx2026-10-15 05:00 EST

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

View all latest news

Coherus BioSciences, Inc.

Immuno-Oncology Portfolio Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI. Casdozokitug Casdozokitug is an anti-IL-27 antibody being studied...

Recent company news

CHRSCoherus BioSciences, Inc.2026-10-28 20:05 EST

Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

CHRSCoherus BioSciences, Inc.2026-10-26 13:30 EST

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

CHRSCoherus BioSciences, Inc.2026-09-23 13:30 EST

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

Stock data

Close
0.75 USD
Market cap
234.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States